Augustine Chemparathy

Augustine Chemparathy

Auto-generated profile, based on publicly available information

Augustine Chemparathy

Stanford University, Stanford, CA USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
XLXueqiu Lin
Xueqiu Lin
YLYanxia Liu
Yanxia Liu
ACAugustine Chemparathy
Augustine Chemparathy
TPTara Pande
Tara Pande
MRMarie La Russa
Marie La Russa
LQLei S. Qi
Lei S. Qi
The COVID-19 pandemic caused by SARS-CoV-2 and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, termed prophylactic antiviral CRISPR in human (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus. Here, we expand in silico analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 crRNAs is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches. We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses in order to facilitate development of CRISPR-based antivirals.

1 February 2024 in Neurology Genetics
Verified
Journal Article
Open access
ACAugustine Chemparathy
Augustine Chemparathy
YGYann Le Guen
Yann Le Guen
YZYi Zeng
Yi Zeng
JGJohn Gorzynski
John Gorzynski
TJTanner D. Jensen
Tanner D. Jensen
MGMichael D. Greicius
Michael D. Greicius
Single-nucleotide variants near TMEM106B associate with the risk of frontotemporal lobar dementia with TDP-43 inclusions (FTLD-TDP) and Alzheimer disease (AD) in genome-wide association studies (GWASs), but the causal variant at this locus remains unclear. Here, we asked whether a novel structural variant on TMEM106B is the causal variant. An exploratory analysis identified structural variants on neurodegeneration-related genes. Subsequent analyses focused on an Alu element insertion on the 3'UTR of TMEM106B. This study included data from longitudinal aging and neurogenerative disease cohorts at Stanford University, case-control cohorts in the Alzheimer Disease Sequencing Project (ADSP), and expression and proteomics data from Washington University in St. Louis (WUSTL). Four hundred thirty-two individuals from 2 Stanford aging cohorts were whole-genome long-read and short-read sequenced. A total of 16,906 samples from ADSP were short-read sequenced. Genotypes, transcriptomics, and proteomics data were available in 1,979 participants from an aging and dementia cohort at WUSTL. Selection criteria were specific to each cohort. In primary analyses, the linkage disequilibrium between the TMEM106B locus variants in the FTLD-TDP GWAS and the 3'UTR insertion was estimated. We then estimated linkage by ancestry in the ADSP and evaluated the effect of the TMEM106B lead variant on mRNA and protein levels. The primary analysis included 432 participants (52.5% female, age range 45-92 years). We identified a 316 bp Alu insertion overlapping the TMEM106B 3'UTR tightly linked with top GWAS variants rs3173615(C) and rs1990622(A). In ADSP European ancestry participants, this insertion is in equivalent linkage with rs1990622(A) (R2 = 0.962, D' = 0.998) and rs3173615(C) (R2 = 0.960, D' = 0.996). In African ancestry participants, the insertion is in stronger linkage with rs1990622(A) (R2 = 0.992, D' = 0.998) than with rs3173615(C) (R2 = 0.811, D' = 0.994). In public data sets, rs1990622 was consistently associated with TMEM106B protein levels but not with mRNA expression. In the WUSTL data set, rs1990622 is associated with TMEM106B protein levels in plasma and CSF, but not with TMEM106B mRNA expression. We identified a novel Alu element insertion in the 3'UTR of TMEM106B in tight linkage with the lead FTLD-TDP risk variant. The lead variant is associated with TMEM106B protein levels, but not expression. The 3'UTR insertion is a lead candidate for the causal variant at this complex locus, pending confirmation with functional studies.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
YGYann Le Guen
Yann Le Guen
ACAugustine Chemparathy
Augustine Chemparathy
SCSunny Chen
Sunny Chen
LLLesley Leong
Lesley Leong
JGJohn John Gorzynski
John John Gorzynski
MGMichael D Greicius
Michael D Greicius
Background: The ε4 variant of APOE is the strongest genetic risk factor for late‐onset Alzheimer’s disease (AD). It remains unclear if the ε4 protein increases AD risk through a gain of abnormal function, or whether it functions less well than the ε3 protein. Framed bluntly: Would knocking down ε4 in an ε4 carrier increase or decrease AD risk?Method: We searched whole‐exomes and whole‐genomes from ∼47,000 older controls and AD cases in the Alzheimer’s Disease Sequencing Project (ADSP) looking for early loss‐of‐function variants on APOE. Five of 26,605 older controls carried a loss‐of‐function variant while only one of 20,856 AD cases did (Figure.1A/B). We reasoned that if ε4 does not function as well as ε3, then loss‐of‐function of either ε3 or ε4 should have an ε4‐like impact on risk. However, if ε4 is inherently detrimental, loss‐of‐function of ε4, specifically, should have a protective effect.Result: Loss of ε3 was seen in two cognitively healthy ε3 homozygotes, last assessed at ages 82 and 88. This suggests that the ε3/null effective genotype is not a strong driver of AD risk. Subject 6‐nominally ε3/ε4 but effectively ε4/null ‐developed symptoms at 75 and died at 87 with autopsy‐confirmed AD, with an age‐at‐onset similar to typical ε3/ε4 (μ = 73.5y), but later typical than ε4/ε4 (μ = 69.7y). This suggests that the loss of ε3 does not result in an ε4‐like phenotype, as seen with Subjects 3 and 5. The most illustrative phenotypes are seen in Subjects 1 and 2 who are nominally ε3/ε4 but effectively ε3/null. Subject 2 was cognitively healthy at 79, with normal levels of amyloid and tau in cerebrospinal fluid at 76, while 2/3rds of ε3/ε4 are amyloid‐positive by 75. Subject 1 was assessed as cognitively normal at 90, died the same year, and had no amyloid pathology, and no amyloid deposits in the cerebral blood vessels, making him a prominent outlier compared to 1700 ε3/ε4 individuals in NACC (Figure.1C).Conclusion: Taken together, these results provide the strongest human genetics evidence yet available to support the hypothesis that ε4 drives AD risk through a gain of abnormal function and that reducing ε4 should be expected to reduce AD risk.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
LTLia Talozzi
Lia Talozzi
ACAugustine Chemparathy
Augustine Chemparathy
TJTanner D. Jensen
Tanner D. Jensen
JGJohn Gorzynski
John Gorzynski
MBMichael E Belloy
Michael E Belloy
MGMichael D Greicius
Michael D Greicius
Background: Alzheimer’s disease (AD) is up to 60‐80% heritable, but less than ∼20% is explained by studies analyzing single nucleotide variants (SNVs). One limitation of short‐read whole‐genome sequencing (SRS) is the standard read length of 150 base pairs, which does not enable the detection of longer structural variants (SVs). Here we sequenced individuals using long‐read sequencing (LRS), which can sequence reads with an average length of ∼20 kilobases, allowing us to identify SVs previously uncaptured.Method: All participants underwent whole‐genome LRS (∼15x coverage) and a subgroup (84%) underwent SRS. Out of 576 participants (47% males, age = 70.6±7.9 y.o.), 115 were diagnosed with AD or mild cognitive impairment, 365 were healthy controls, and 96 were diagnosed with a synucleinopathy (either Parkinson or Lewy Body disease). Eighty‐three index SNVs from loci associated with AD risk through GWAS (Bellenguez et al., Nature Genetics 2022) were genotyped with 30x coverage SRS, in addition to APOE2‐4. A 1Mbp window was defined around these SNVs to construct the discovery range for SVs (Sniffles2 population mode). Linkage disequilibrium (LD) was assessed between SNVs and SVs (CubeX).Result: A total of 14854 SVs were found across the AD risk loci (Figure1). After LD calculation, N = 197 SVs had a R2>0.1 (Figure2). The SVs with the highest LD (R2>0.7) are reported in Table1, among which there is a 322 bp deletion in the 3’ UTR region of the TMEM106B in high LD (R2 = 0.918) with the intronic SNV rs13237518. This TMEM106B locus has been previously associated with the risk of frontotemporal lobar dementia with TDP‐43 pathology in addition to AD, but the causative SNV has not been identified yet. This large deletion may mediate TMEM106B’s risk‐modulating role in AD and FTLD‐TDP (Chemparathy et al. medRxiv 2023). At the complex MAPT locus, three SVs showed a high LD with rs199515.Conclusion: Insights into the role of SVs in neurodegenerative disorders have been hampered due to limitations with SRS. Using LRS in a large AD‐related sample, we characterized for the first time the genetic variation of SVs in known AD risk loci and provide a roadmap to identify potential causal SVs driving the AD association signal.